Author:
Rosovsky Rachel P.,Crowther Mark A.
Abstract
Abstract
A 47-year-old man presents with hypovolemic shock. He takes warfarin as a result of a mechanical mitral valve insertion 5 years prior, his INR at presentation is 8.4 and emergent CT reveals a very large retroperitoneal hematoma. Despite aggressive fluid and transfusion support he continues hypotensive, requiring ionotrope support. You are asked if he should receive recombinant factor VIIa.
Publisher
American Society of Hematology
Reference26 articles.
1. Abu-Hajir M, Hollowell J, Nagargoje G. Management of 2 patients with subdural hematoma and coagulopathy with recombinant human activated Factor VIIa (NovoSeven, rVIIa). Blood. 2001;98:79b.
2. Erhardtsen E, Nony P, Dechavanne M, Ffrench P, Boissel JP, Hedner U. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolysis. 1998;9:741–748.
3. Muleo G, Santoro R, Iannaccaro PG, et al. Small doses of recombinant factor VIIa in acquired deficiencies of vitamin K dependent factors. Blood Coagul Fibrinolysis. 1999;10:521–522.
4. Shopnick R. Reversal of warfarin using recombinant factor VIIa prior to invasive procedures. Blood. 2001;98:99b.
5. Aguilar MI, Hart RG, Kase CS, et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc. 2007;82:82–92.
Cited by
53 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献